NCT00046150View on ClinicalTrials.gov

12 Week,Comparing Safety of HMR1964 & Insulin Aspart Used in Continuous Subcutaneous Infusion in Type 1 Diabetes.

PHASE3CompletedINTERVENTIONAL
Enrollment

59

Participants

Timeline

Start Date

May 31, 2002

Study Completion Date

December 31, 2002

Conditions
Diabetes, Type I
Interventions
DRUG

Insulin glulisine (HMR1964)

Trial Locations (3)

31403

Hospital de Rangueil, Toulouse

Unknown

Sanofi-aventis Administrative Office, Berlin

Sanofi-aventis Administrative Office, Gouda

Sponsors

Lead Sponsor

Sanofi
All Listed Sponsors
lead

Sanofi

INDUSTRY